BR112012006579A2 - agonistas de npr-b. - Google Patents

agonistas de npr-b.

Info

Publication number
BR112012006579A2
BR112012006579A2 BR112012006579A BR112012006579A BR112012006579A2 BR 112012006579 A2 BR112012006579 A2 BR 112012006579A2 BR 112012006579 A BR112012006579 A BR 112012006579A BR 112012006579 A BR112012006579 A BR 112012006579A BR 112012006579 A2 BR112012006579 A2 BR 112012006579A2
Authority
BR
Brazil
Prior art keywords
npr
agonists
unconventional
pot
bonds
Prior art date
Application number
BR112012006579A
Other languages
English (en)
Portuguese (pt)
Inventor
Bernadett Simon
Edgar Specker
Frank Osterkamp
Gerd Hummel
Heiko Hawlisch
Mark R Hellberg
Markus Woischnik
Tobias Knaute
Ulf Reimer
Ulrich Reineke
Uwe Richter
Original Assignee
Alcon Res Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43781057&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR112012006579(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Alcon Res Ltd filed Critical Alcon Res Ltd
Publication of BR112012006579A2 publication Critical patent/BR112012006579A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/2242—Atrial natriuretic factor complex: Atriopeptins, atrial natriuretic protein [ANP]; Cardionatrin, Cardiodilatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/58—Atrial natriuretic factor complex; Atriopeptin; Atrial natriuretic peptide [ANP]; Cardionatrin; Cardiodilatin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/02—Linear peptides containing at least one abnormal peptide link
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Zoology (AREA)
  • Endocrinology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Toxicology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
BR112012006579A 2009-09-25 2010-09-23 agonistas de npr-b. BR112012006579A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US24596009P 2009-09-25 2009-09-25
PCT/US2010/049912 WO2011038061A2 (en) 2009-09-25 2010-09-23 Novel npr-b agonists

Publications (1)

Publication Number Publication Date
BR112012006579A2 true BR112012006579A2 (pt) 2016-11-22

Family

ID=43781057

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112012006579A BR112012006579A2 (pt) 2009-09-25 2010-09-23 agonistas de npr-b.

Country Status (17)

Country Link
US (5) US8546523B2 (https=)
EP (1) EP2480247B1 (https=)
JP (3) JP5893561B2 (https=)
KR (3) KR20180049198A (https=)
CN (2) CN102548574B (https=)
AR (1) AR078445A1 (https=)
AU (1) AU2010298256B2 (https=)
BR (1) BR112012006579A2 (https=)
CA (1) CA2773949C (https=)
CL (2) CL2012000715A1 (https=)
MX (3) MX354005B (https=)
PH (1) PH12012500562A1 (https=)
RU (3) RU2636738C2 (https=)
TW (2) TWI625126B (https=)
UY (1) UY32902A (https=)
WO (1) WO2011038061A2 (https=)
ZA (3) ZA201201630B (https=)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2510942T3 (en) 2005-04-07 2015-12-14 Cardiorentis Ag Use of natriuretic peptides for the treatment of heart failure
EP2054044B1 (de) * 2006-08-02 2014-07-23 Johannes Gutenberg-Universität Mainz Arzneimittel gegen lct-vergiftungen
EP2480247B1 (en) * 2009-09-25 2020-02-12 Shire Orphan Therapies GmbH Novel npr-b agonists
AR078446A1 (es) 2009-12-18 2011-11-09 Alcon Res Ltd Agonistas de npr-b. uso.
CN108653715A (zh) * 2011-12-16 2018-10-16 卡乐斯治疗公司 用于治疗视网膜病症和疾病的anp、bnp以及cnp相关肽及其衍生物的方法和用途
US20140213520A1 (en) * 2013-01-25 2014-07-31 Cardiorentis Ltd. Methods of treating cardiovascular indications
EP4067368A1 (en) 2016-06-01 2022-10-05 Athira Pharma, Inc. Compounds
EP3576770A1 (en) 2017-02-01 2019-12-11 Shire Human Genetic Therapies, Inc. Compounds and compositions for the treatment of ophthalmic disorders
EP3810082A1 (en) * 2018-06-19 2021-04-28 Cella Therapeutics, LLC Sustained-release drug delivery systems comprising an intraocular pressure lowering agent, a cnp compound, an npr-b compound, a tie-2 agonist, or neurotrophic agent for use for treating glaucoma or ocular hypertension
ES3034676T3 (en) * 2018-11-16 2025-08-21 Arcus Biosciences Inc Inhibitors of arg1 and/or arg2
IL298980A (en) * 2020-06-12 2023-02-01 Pharmain Corp C-type natriuretic peptides and methods thereof in treating acute lung injury
KR102677730B1 (ko) * 2023-03-27 2024-06-27 나인바이오팜 주식회사 지방 분해 효능을 갖는 펩타이드 및 이의 용도

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4757048A (en) 1985-11-05 1988-07-12 Biotechnology Research Associates J.V. Synthetic analogs of atrial natriuretic peptides
AU2927889A (en) * 1987-12-24 1989-07-19 California Biotechnology, Inc. Linear analogs of atrial natriuretic peptides
WO1990001940A1 (en) 1988-08-18 1990-03-08 California Biotechnology Inc. Atrial natriuretic peptide clearance inhibitors
CN1169573C (zh) 1998-09-28 2004-10-06 参天制药株式会社 用于治疗角结膜障碍的、包含作为活性组分的钠尿肽的泪液分泌促进剂或滴眼剂
US20040266673A1 (en) 2002-07-31 2004-12-30 Peter Bakis Long lasting natriuretic peptide derivatives
US6025198A (en) 1999-06-25 2000-02-15 Isis Pharmaceuticals Inc. Antisense modulation of Ship-2 expression
US6436703B1 (en) * 2000-03-31 2002-08-20 Hyseq, Inc. Nucleic acids and polypeptides
IL142118A0 (en) * 2001-03-20 2002-03-10 Prochon Biotech Ltd Method and composition for treatment of skeletal dysplasias
TWI231759B (en) 2001-06-27 2005-05-01 Alcon Inc Olopatadine formulations for topical administration
US7648962B2 (en) * 2002-11-26 2010-01-19 Biocon Limited Natriuretic compounds, conjugates, and uses thereof
US7297709B2 (en) 2003-05-22 2007-11-20 Abbott Laboratories Indazole, benzisoxazole, and benzisothiazole kinase inhibitors
ATE496060T1 (de) * 2004-07-15 2011-02-15 Univ Queensland Proteinartige verbindungen und anwendungen davon
TW200640443A (en) 2005-02-23 2006-12-01 Alcon Inc Methods for treating ocular angiogenesis, retinal edema, retinal ischemia, and diabetic retinopathy using selective RTK inhibitors
WO2007034498A1 (en) 2005-09-26 2007-03-29 Compugen Ltd. Atrial natriuretic peptide (anp) splice variants and methods of using same
EP1951277A2 (en) * 2005-10-14 2008-08-06 Biorexis Pharmaceutical Corporation Natriuretic peptide modified transferrin fusion proteins
US7795221B2 (en) * 2006-03-30 2010-09-14 Palatin Technologies, Inc. Linear natriuretic peptide constructs
EP2001518B1 (en) * 2006-03-30 2013-07-10 Palatin Technologies, Inc. Cyclic natriuretic peptide constructs
AR069409A1 (es) * 2007-11-21 2010-01-20 Biomarin Pharm Inc Variantes de peptidos natriureticos de tipo c
EP2480247B1 (en) 2009-09-25 2020-02-12 Shire Orphan Therapies GmbH Novel npr-b agonists
US8551938B2 (en) 2009-09-25 2013-10-08 Alcon Research, Ltd. NPR-B agonists
AR078446A1 (es) 2009-12-18 2011-11-09 Alcon Res Ltd Agonistas de npr-b. uso.

Also Published As

Publication number Publication date
CL2017001190A1 (es) 2017-12-01
KR101768661B1 (ko) 2017-08-16
KR101854820B1 (ko) 2018-05-04
RU2015124607A (ru) 2015-12-10
TWI577384B (zh) 2017-04-11
CA2773949C (en) 2020-11-03
AU2010298256B2 (en) 2015-08-13
WO2011038061A3 (en) 2011-07-28
EP2480247A2 (en) 2012-08-01
JP2015131856A (ja) 2015-07-23
MX2012003398A (es) 2012-04-10
US20170313743A1 (en) 2017-11-02
KR20180049198A (ko) 2018-05-10
ZA201702958B (en) 2018-08-29
CN105732767A (zh) 2016-07-06
US9169293B2 (en) 2015-10-27
RU2557290C2 (ru) 2015-07-20
US9745344B2 (en) 2017-08-29
KR20120091110A (ko) 2012-08-17
TWI625126B (zh) 2018-06-01
ZA201201630B (en) 2014-05-28
MX370645B (es) 2019-12-19
PH12012500562A1 (en) 2012-10-22
CA2773949A1 (en) 2011-03-31
CN102548574B (zh) 2016-03-23
ZA201401625B (en) 2018-08-25
AU2010298256A1 (en) 2012-04-12
US20130345394A1 (en) 2013-12-26
CN102548574A (zh) 2012-07-04
KR20170094564A (ko) 2017-08-18
US8546523B2 (en) 2013-10-01
AR078445A1 (es) 2011-11-09
EP2480247A4 (en) 2013-09-04
US20110077381A1 (en) 2011-03-31
WO2011038061A2 (en) 2011-03-31
JP6211032B2 (ja) 2017-10-11
TW201630619A (zh) 2016-09-01
RU2012116531A (ru) 2013-10-27
US20180334477A1 (en) 2018-11-22
US9982016B2 (en) 2018-05-29
US20160194357A1 (en) 2016-07-07
RU2636738C2 (ru) 2017-11-28
RU2017139870A3 (https=) 2019-05-16
JP2013505937A (ja) 2013-02-21
UY32902A (es) 2011-02-28
TW201110974A (en) 2011-04-01
CL2012000715A1 (es) 2012-11-30
JP5893561B2 (ja) 2016-03-23
EP2480247B1 (en) 2020-02-12
MX354005B (es) 2018-02-08
JP2017137362A (ja) 2017-08-10
RU2017139870A (ru) 2019-05-16
US10196423B2 (en) 2019-02-05

Similar Documents

Publication Publication Date Title
BR112012006579A2 (pt) agonistas de npr-b.
ES2531288T3 (es) Proteína de fusión anticancerígena
IN2014CN02050A (https=)
CL2013003416A1 (es) Secuencia de peptidos quiméricos que comprende dsspl o dasph composiciones , usos y metodo para mejorar metabolismo de glucosa.
NZ600732A (en) Oxyntomodulin peptide analogue
UA103215C2 (uk) Поліпептид з ксиланазною активністю
DE602005008996D1 (de) Radiofluorierte peptide
CA2839298C (en) Anti-inflammatory pharmaceutical products
JP2010265269A5 (https=)
ATE453664T1 (de) Hausstaubmilbenallergen
EP3263123A3 (en) Shk-based pharmaceutical compositions and methods of manufacturing and using the same
CY1111630T1 (el) Παραγωγα κυτοκινων
MX2010010213A (es) Peptido parcial de lacritina.
MX2010005816A (es) Epítopos de péptido de stat3.
ATE451112T1 (de) Oligopeptide enthaltende dermatologische zusammensetzungen zur steigerung der hautempfindlichkeit
EP2614075A4 (en) UNILATED RELAXIN POLYPEPTIDES
NZ589365A (en) Peptidyl diacylglycerides
EA201590431A1 (ru) Пшеница с новыми аллелями rht-b1
NZ706202A (en) Peptide antagonists of the vasopressin-2 receptor
UY32908A (es) Nuevos agonistas de npr-b
NZ591133A (en) Novel melanoma antigen peptide and uses thereof
ATE467643T1 (de) Peptide mit proliferationshemmender wirkung
ES2573462T3 (es) Polipéptidos de PH20 soluble extendida y usos de los mismos
RU2008148880A (ru) Семейство пептидов, обладающее противовирусной активностью
GB201019467D0 (en) Therapeutic agent

Legal Events

Date Code Title Description
B25A Requested transfer of rights approved

Owner name: SHIRE ORPHAN THERAPIES GMBH (US)

B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B25A Requested transfer of rights approved

Owner name: TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP)

B11B Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements